Swedish biotechnology company Active Biotech AB (STO:ACTI) on Monday provided an update on its clinical phase Ib/IIa study of tasquinimod in relapsed refractory multiple myeloma (RRMM) patients.
The study is ongoing at the Abramson Cancer Center, University of Pennsylvania. Data from 11 patients treated with tasquinimod in combination with ixazomib, lenalidomide and dexamethasone (IRd) shows no unexpected toxicity and good tolerability.
Three patients demonstrated clinical benefit, including one partial response and two minimal responses, among nine patients refractory to prior proteasome inhibitor and immunomodulatory drug regimens. The study aims to enrol up to six additional patients refractory to their most recent proteasome inhibitor/immunomodulatory drug combination.
Principal investigator Dr Dan Vogl highlighted the clinically meaningful disease responses in highly refractory patients, suggesting tasquinimod's potential to overcome treatment resistance and improve myeloma therapies.
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Oxford BioDynamics announces distribution agreement with Regina Maria for EpiSwitch tests in Romania
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
Hoth Therapeutics and OnTargetx R&D partner on cancer research
CStone Pharmaceuticals' Cejemly included in ESMO NSCLC Living Guideline
TransCode Therapeutics enrols three patients in Cohort 3 of TTX-MC138 Phase 1 clinical trial
Biohit partners with Restalyst to enhance early gastric cancer detection
Henlius's serplulimab approved in Europe for Extensive-Stage Small Cell Lung Cancer
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Oxford BioDynamics reports high accuracy for blood-based colorectal cancer test
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer